PubMed Health⌕ Search

Biomedical subjects

D A Knapp

Publications and source records attributed to D A Knapp.

At least 37 records · Page 2Linked to original sources

Evaluation of antihypertensive drug prescribing in a primary care clinic.

Although the National High Blood Pressure Education Program has been in existence since the early 1970's, reported evaluation of drug prescribing for ambulatory, hypertensive patients for conformance with the stepped-care approach and approved drug labeling is lacking in the literature. To study this, charts of hypertensive patients from a primary care clinic were retrospectively reviewed against explicit treatment criteria. It was found that nearly all the antihypertensive drug prescribing was in accord with the criteria, with the exception of the scheduling of return visits to the clinic and monitoring. The community pharmacist's role in improving patient monitoring is discussed.

Ambulatory Care Facilities↗

Strategy for increasing the demand for clinical pharmacists.

A strategy for increasing the demand for clinical pharmaceutical services in hospitals is described. The strategy consists of three steps: (1) Show that the overall quality of drug prescribing affects patient outcomes not only in a negative way but also in a positive manner; i.e., appropriate prescribing speeds recovery and minimizes the need for more expensive types of care; (2) show that the pharmacist can detect poor quality prescribing; and (3) show that after detecting poor quality prescribing, the clinical pharmacist can effectively intervene in the prescribing process to reduce inappropriate prescribing and improve patient outcomes.

Drug Prescriptions↗

Low cost, manual drug use review of Medicaid recipients to screen prescriber and pharmacist performance.

A manual drug use review (DUR) methodology to screen outpatient prescribing which would meet the needs of large third-party programs that cannot afford elaborate computerized DUR was developed and pilot tested. A Medicaid drugs data base was used for the pilot test. A probability sample of 100 recipients over a three-month period was selected for the DUR. The drugs for each recipient, listed by their generic composition and amount, were recorded. Then a priori, explicit, screening criteria were developed for these generics. These criteria delineated drugs of choice, daily dose and refill patterns and, as appropriate, therapy length, drug holidays, and disease-drug and drug-drug interactions. Only 11% of recipients had prescribing patterns which passed all the screens. The most frequent screening failure was due to the prescribing of a drug which was not a drug of choice. In nearly all of the cases which failed the other screens, an alert pharmacist with patient records should have noticed these problems. An analysis showed that the initial start-up cost for the manual DUR was estimated at $1053 (not including personnel fringe benefits); for subsequent quarterly review, the cost was estimated to be about $530. The project showed that manual DUR can effectively and efficiently screen prescribing in a large third-party program.

Costs and Cost Analysis↗

Can pharmacists influence drug prescribing? A look at eight of the top 25 drug products for 1976.

The most frequently prescribed drug products were reviewed for insights into prescribing and dispensing patterns for ambulatory patients. The indications for eight of the "top" drug products were considered to be pharmacologically or therapeutically questionable. The drug products were: tetracycline, systemic; Dimetapp; Empirin Compound with Codeine; Actified; Darvon Compound 65; Darvocet-N; Donnatal; and Keflex. Drug prescribing review and prescriber education are crucially needed, as well as formulary controls when feasible.

Drug Utilization↗

Detecting prescribing problems through drug usage review: a case study.

A retrospective drug usage review was performed on 1,033 randomly sampled prescription orders from the outpatient pharmacy of a hospital and clinic system. Prescription orders were screened in accordance with criteria based on daily dosage, length of therapy or quantity dispenced, diagnosis, and labeling. The results of the study point to a number of potential prescribing problems. In addition, the study demonstrates the feasibility of collecting and analyzing drug usage data on a retrospective basis.

Diagnosis↗

Drug usage screening criteria.

Screening criteria for adult use of 40 drugs and pediatric use of 10 drugs are presented. The reasons for presenting the criteria are to (1) document the specific screening criteria applied in a number of drug usage review studies, (2) provide a starting point for other groups wishing to develop criteria for drug usage review and (3) seek comments to be used in improving the criteria.

Drug Labeling↗